Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Standard
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. / Haese, Alexander; de La Taille, Alexandre; van Poppel, Hendrik; Marberger, Michael; Stenzl, Arnulf; Mulders, Peter F A; Huland, Hartwig; Abbou, Clément-Claude; Remzi, Mesut; Tinzl, Martina; Feyerabend, Susan; Stillebroer, Alexander B; Gils, van; Martijn, P M Q; Schalken, Jack A.
in: EUR UROL, Jahrgang 54, Nr. 5, 5, 2008, S. 1081-1088.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
AU - Haese, Alexander
AU - de La Taille, Alexandre
AU - van Poppel, Hendrik
AU - Marberger, Michael
AU - Stenzl, Arnulf
AU - Mulders, Peter F A
AU - Huland, Hartwig
AU - Abbou, Clément-Claude
AU - Remzi, Mesut
AU - Tinzl, Martina
AU - Feyerabend, Susan
AU - Stillebroer, Alexander B
AU - Gils, van
AU - Martijn, P M Q
AU - Schalken, Jack A
PY - 2008
Y1 - 2008
N2 - BACKGROUND: The Prostate CAncer gene 3 (PCA3) assay has shown promise as an aid in prostate cancer (pCA) diagnosis in identifying men with a high probability of a positive (repeat) biopsy. OBJECTIVE: This study evaluated the clinical utility of the PROGENSA PCA3 assay. DESIGN, SETTING, AND PARTICIPANTS: This European prospective, multicentre study enrolled men with one or two negative biopsies scheduled for repeat biopsy. MEASUREMENTS: After digital rectal examination (DRE), first-catch urine was collected to measure PCA3 mRNA concentration and to calculate the PCA3 score. The PCA3 score was compared to biopsy outcome. The diagnostic accuracy of the PCA3 assay was compared to percent of free prostate-specific antigen (%fPSA). RESULTS AND LIMITATIONS: In 463 men, the positive repeat biopsy rate was 28%. The higher the PCA3 score, the greater the probability of a positive repeat biopsy. The PCA3 score (cut-off of 35) had a greater diagnostic accuracy than %fPSA (cut-off of 25%). The PCA3 score was independent of the number of previous biopsies, age, prostate volume, and total prostate-specific antigen (PSA) level. Moreover, the PCA3 score was significantly higher in men with high-grade prostate intraepithelial neoplasia (HGPIN) versus those without HGPIN, clinical stage T2 versus T1, Gleason score >or=7 versus
AB - BACKGROUND: The Prostate CAncer gene 3 (PCA3) assay has shown promise as an aid in prostate cancer (pCA) diagnosis in identifying men with a high probability of a positive (repeat) biopsy. OBJECTIVE: This study evaluated the clinical utility of the PROGENSA PCA3 assay. DESIGN, SETTING, AND PARTICIPANTS: This European prospective, multicentre study enrolled men with one or two negative biopsies scheduled for repeat biopsy. MEASUREMENTS: After digital rectal examination (DRE), first-catch urine was collected to measure PCA3 mRNA concentration and to calculate the PCA3 score. The PCA3 score was compared to biopsy outcome. The diagnostic accuracy of the PCA3 assay was compared to percent of free prostate-specific antigen (%fPSA). RESULTS AND LIMITATIONS: In 463 men, the positive repeat biopsy rate was 28%. The higher the PCA3 score, the greater the probability of a positive repeat biopsy. The PCA3 score (cut-off of 35) had a greater diagnostic accuracy than %fPSA (cut-off of 25%). The PCA3 score was independent of the number of previous biopsies, age, prostate volume, and total prostate-specific antigen (PSA) level. Moreover, the PCA3 score was significantly higher in men with high-grade prostate intraepithelial neoplasia (HGPIN) versus those without HGPIN, clinical stage T2 versus T1, Gleason score >or=7 versus
M3 - SCORING: Zeitschriftenaufsatz
VL - 54
SP - 1081
EP - 1088
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 5
M1 - 5
ER -
